Celcuity Inc. CELC
68.68 USD +1.89 (+2.83%)
Nov 9, 2026, 10:01 AM EST
66.40 Day range 68.99
53.54 52-week range 151.02
- YTD
- -31.14%
- 1 year
- -7.84%
News
benzinga.com Celcuity's Supplemental New Drug Application For REVTORPYK Accepted for FDA Review To Treat Hormone Receptor Positive Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today…
benzinga.com Block To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Monday Analysts raised targets for Magnite, Airbnb and Choice Hotels; cut targets for Unusual Machines, DraftKings, PDD and TeraWulf. DKNG and PDD downgraded.
benzinga.com HC Wainwright & Co. Maintains Buy on Celcuity, Lowers Price Target to $150 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target from $155 to $150.
benzinga.com Guggenheim Maintains Buy on Celcuity, Lowers Price Target to $169 Guggenheim analyst Michael Schmidt maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target from $171 to $169.
marketbeat.com What Celcuity (CELC) Said on Its Q3 Earnings Call Celcuity NASDAQ: CELC reported a wider third-quarter loss as it prepared to commercialize its breast cancer treatment REVTORPYK, while executives said early orders and insurance coverage pointed to…
benzinga.com Celcuity Q3 2026 Earnings Call Transcript Celcuity (NASDAQ:CELC) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…- benzinga.com Celcuity Q3 Adj. EPS $(1.21) Beats $(1.43) Estimate, Sales $0.00 Miss $1.563M Estimate Celcuity (NASDAQ:CELC) reported quarterly losses of $(1.21) per share which beat the analyst consensus estimate of $(1.43) by 15.38 percent. This is a 55.13 percent decrease over losses of $(0.78)…
globenewswire.com Celcuity To Participate in Upcoming Investor Conferences MINNEAPOLIS, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid…
benzinga.com Cantor Fitzgerald Initiates Coverage On Celcuity with Overweight Rating, Announces Price Target of $140 Cantor Fitzgerald analyst Li Watsek initiates coverage on Celcuity (NASDAQ:CELC) with a Overweight rating and announces Price Target of $140.
benzinga.com Needham Maintains Buy on Celcuity, Lowers Price Target to $134 Needham analyst Gil Blum maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target from $140 to $134.- benzinga.com Celcuity Announces Commercial Availability Of REVTORPYK In U.S. For People With Hormone Receptor-Positive Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that…
- benzinga.com JP Morgan Initiates Coverage On Celcuity with Overweight Rating, Announces Price Target of $157 JP Morgan analyst Anupam Rama initiates coverage on Celcuity (NASDAQ:CELC) with a Overweight rating and announces Price Target of $157.
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Celcuity Files Supplemental New Drug Application To FDA For REVTORPYK To Treat Breast Cancer Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its…- benzinga.com Guggenheim Maintains Buy on Celcuity, Raises Price Target to $175 Guggenheim analyst Brad Canino maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price target from $165 to $175.
benzinga.com Citizens Reiterates Market Outperform on Celcuity, Maintains $177 Price Target Citizens analyst Silvan Turkcan reiterates Celcuity (NASDAQ:CELC) with a Market Outperform and maintains $177 price target.
benzinga.com HC Wainwright & Co. Reiterates Buy on Celcuity, Maintains $155 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $155 price target.
benzinga.com Celcuity Analysts Slash Their Forecasts After Q2 Loss Celcuity Inc (NASDAQ:CELC) reported better-than-expected Q2 losses of $1.07 per share. Analysts are optimistic with price target cuts by Needham and Stifel.- benzinga.com Stifel Maintains Buy on Celcuity, Lowers Price Target to $150 Stifel analyst Stephen Willey maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target from $175 to $150.
- benzinga.com Needham Maintains Buy on Celcuity, Lowers Price Target to $140 Needham analyst Gil Blum maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target from $157 to $140.
benzinga.com Celcuity Reports Q2 2026 Results: Full Earnings Call Transcript On Thursday, Celcuity (NASDAQ:CELC) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call…- benzinga.com Celcuity Q2 Adj. EPS $(1.07) Beats $(1.17) Estimate Celcuity (NASDAQ:CELC) reported quarterly losses of $(1.07) per share which beat the analyst consensus estimate of $(1.17) by 7.76 percent. This is a 15.05 percent decrease over losses of $(0.93) per…
- benzinga.com Celcuity's REVTORPYK Receives Recommendation From National Comprehensive Cancer Network Clinical Practice Guidelines In Oncology As Preferred Category 1 Second-Line Therapy Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced that REVTORPYK™ (gedatolisib)…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers China Pharma Holding (AMEX:CPHI) shares moved upwards by 67.6% to $1.03 during Wednesday's regular session. The market value of their outstanding shares is at $24.9 million. Conexeu Sciences…- benzinga.com Citizens Maintains Market Outperform on Celcuity, Raises Price Target to $177 Citizens analyst Silvan Turkcan maintains Celcuity (NASDAQ:CELC) with a Market Outperform and raises the price target from $160 to $177.
benzinga.com CrowdStrike To Rally Over 12%? Here Are 10 Top Analyst Forecasts For Wednesday Top Wall Street analysts changed outlook on top names. See all changes, including upgrades/downgrades, on our analyst ratings page.- benzinga.com HC Wainwright & Co. Maintains Buy on Celcuity, Raises Price Target to $155 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price target from $145 to $155.
benzinga.com Palo Alto Networks To Rally Nearly 70%? Here Are 10 Notable Analyst Calls From Wednesday Top Wall Street analysts changed outlook on top names. For all rating changes, upgrades and downgrades, visit analyst ratings page.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Earnings Scheduled For May 14, 2026 
benzinga.com Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Other Big Stocks Moving Higher On Monday Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday after reporting better-than-expected financial results. Other top gainers included companies like…
benzinga.com This Prudential Financial Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday Wall Street analysts changed outlook on top names, including PRU, ARE, TRGP, VITL, and GOOGL. See analyst ratings page for more info.- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com This First Tracks Biotherapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday Top Wall Street analysts changed outlook on top stocks. See analyst ratings page for changes, including upgrades, downgrades, and initiations.
benzinga.com This Airbnb Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday Wall Street analysts upgraded and raised price targets for ESS, SITE, PKG, ABNB, and CELC. See what other analysts think before buying ABNB stock.
benzinga.com Packaging Corp Of America To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday Needham analyst Rick Patel maintained a Buy rating. Steven Madden shares closed at $47.27 on Friday. Top analysts change outlook on BTSG, CELC, ESS, CORT, PKG, PRU, RVTY, and SHOO. See how they rate…
benzinga.com Why eBay Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket eBay (NASDAQ: EBAY) rose sharply after GameStop (NYSE: GME) proposed to acquire it for $125/share, valuing GME at $55.5B. eBay shares jumped 8.1% to $112.50 in pre-market trading.- benzinga.com Earnings Scheduled For March 25, 2026
benzinga.com Xpeng, Serina Therapeutics, Dragonfly Energy Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session 
benzinga.com RH Posts Strong Q3 Sales, Joins Canopy Growth, Tilray Brands, Frequency Electronics And Other Big Stocks Moving Higher On Friday - benzinga.com Earnings Scheduled For November 12, 2025
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday 
benzinga.com Dow Jumps Over 200 Points; Cleveland-Cliffs Shares Jump After Q3 Results - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket - benzinga.com Earnings Scheduled For August 14, 2025
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com Alerus Financial Posts Better-Than-Expected Earnings, Joins Celcuity, SES AI, Abercrombie & Fitch And Other Big Stocks Moving Higher On Monday 
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session